General
Preferred name
LISURIDE
Synonyms
Lisuride maleate ()
Dopergin ()
lisuride hydrogen maleate, Sinoxa ()
Lisuride (maleate) ()
Lisurida ()
Revanil 200 ()
Lysuride maleate ()
P&D ID
PD009903
CAS
19875-60-6
18016-80-3
Tags
available
biased GPCR ligand
drug
Drug indication
Parkinson disease
cocaine dependence
Fibrosis
Drug Status
approved
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Lisuride is an antiparkinson agent of the iso-ergoline class, acting principally as a dopamine receptor partial agonist. (GtoPdb)
PHARMACODYNAMICS There is evidence that lisuride lowers prolactin levels and, in low doses, prevents migraine attacks.
MOA Lisuride is an anti-Parkinson drug chemically related to the dopaminergic ergoline Parkinson's drugs. Lisuride binds to the 5-HT(1A) and 5-HT(2A/2C) receptors. It is also thought to bind to the dopamine receptor and to act as a dopamine agonist. Evidence has also emerged that Lisuride also binds to the Histamine H1 receptor.
DESCRIPTION Lisuride is an orally active dopamine D2 receptors agonist. Lisuride, as an ergot derivative, can be used for the research of Parkinson's disease, migraine, and high prolactin levels[1][2].
DESCRIPTION Lisuride (maleate) is a potent agonist of dopamine with a probably direct action on dopaminergic receptors. Lisuride (maleate) is an ergot derivative. Lisuride (maleate) releases the premenstrual mastalgia without significant side effects[1][2].
DESCRIPTION Lisuride, an indoloquinoline derivative, has been found to be a dopamine D2 receptor agonist and could probably be effective in antimigraine as well as antiparkinsonian studies. (BOC Sciences Bioactive Compounds)
DESCRIPTION Potent, selective MC1 receptor agonist (Tocris Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
21
BiasDB
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NPC Screening Collection
ReFrame library
Tocris Bioactive Compound Library
ZINC Tool Compounds
External IDs
122
Properties
(calculated by RDKit )
Molecular Weight
338.21
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
4
Aromatic Ring Count
2
cLogP
2.84
TPSA
51.37
Fraction CSP3
0.45
Chiral centers
2.0
Largest ring
6.0
QED
0.9
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Primary Target
Non-selective Dopamine
MOA
Agonist
Dopamine Receptor agonist
Indication
Parkinson's Disease
Target
ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6
Dopamine Receptor
Biosynthetic Origin
Alkaloid
Therapeutic Indication
Antihyperprolactinemia
Therapeutic Class
CNS & PNS
Antiparkinson Agents
Pathway
GPCR/G protein
Neuronal Signaling
Source data